Catheter Precision, INC Form 4 insider transactions

Catheter Precision Director James Joseph Caruso acquired 40,000 stock options with an exercise price of $1.15, signaling potential confidence in the company's future.

Catheter Precision's Chairman and CEO, David A. Jenkins, reported beneficial ownership of 340,000 Series M Common Stock Purchase Warrants with conflicting expiration dates.

Catheter Precision Director James Joseph Caruso converted Series X Convertible Preferred Stock into 41 shares of common stock.

Catheter Precision's Chairman and CEO, David A. Jenkins, converted Series X Convertible Preferred Stock into common stock, increasing his direct and indirect common stock holdings.

Director Andrew Arno acquired options to purchase 50,000 shares of Catheter Precision, Inc. common stock.

Catheter Precision, Inc. Director Martin J. Colombatto was granted 50,000 stock options with an exercise price of $0.18, vesting over three years.

Catheter Precision Director James Joseph Caruso acquired 50,000 stock options with a $0.18 exercise price, vesting over three years.

Catheter Precision, Inc. has granted 500,000 stock options to Executive Chairman David A. Jenkins, aligning executive incentives with long-term company performance.

Philip J. Anderson, CFO of Catheter Precision, Inc., reports the acquisition of 500,000 options in the company.

A director of Catheter Precision, Inc. has acquired shares and stock options, as detailed in a recent SEC filing.

David Jenkins, Chairman and CEO of Catheter Precision, Inc., reports the acquisition of 450,000 stock options on January 29, 2025.

Marie-Claude Jacques, Chief Commercial Officer of Catheter Precision, Inc., reports the acquisition of stock options.

James Joseph Caruso, a director of Catheter Precision, Inc., acquired stock options exercisable for 100,000 shares of common stock.

Director Andrew Arno acquired stock options for 100,000 shares of Catheter Precision, Inc. (VTAK) on January 29, 2025.

Chief Commercial Officer Jacques Marie-Claude reports the acquisition of stock options in Catheter Precision, Inc.